ERBB2 c.3307A>C ;(p.T1103P)

Variant ID: 17-37883695-A-C

NM_004448.2(ERBB2):c.3307A>C;(p.T1103P)

This variant was identified in 2 publications

View GRCh38 version.




Publications:


A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.

Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Jang, H Josh HJ; Hostetter, Galen G; MacFarlane, Alexander W AW; Madaj, Zachary Z; Ross, Eric A EA; Hinoue, Toshinori T; Kulchycki, Justin R JR; Burgos, Ryan S RS; Tafseer, Mahvish M; Alpaugh, R Katherine RK; Schwebel, Candice L CL; Kokate, Rutika R; Geynisman, Daniel M DM; Zibelman, Matthew R MR; Ghatalia, Pooja P; Nichols, Peter W PW; Chung, Woonbok W; Madzo, Jozef J; Hahn, Noah M NM; Quinn, David I DI; Issa, Jean-Pierre J JJ; Topper, Michael J MJ; Baylin, Stephen B SB; Shen, Hui H; Campbell, Kerry S KS; Jones, Peter A PA; Plimack, Elizabeth R ER
Publication Date: 2023-03-16

Variant appearance in text: ERBB2: T1103P
PubMed Link: 36928921
Variant Present in the following documents:
  • ccr-22-3642_supplementary_tables_1_suppts1.xlsx, sheet 3
View BVdb publication page



Identification of Potential Biomarkers for Liver Cancer Through Gene Mutation and Clinical Characteristics.

Frontiers In Oncology
Cui, Yunlong Y; Li, Hua H; Zhan, Hongjie H; Han, Tao T; Dong, Yixuan Y; Tian, Caijuan C; Guo, Yixian Y; Yan, Fang F; Dai, Dong D; Liu, Pengfei P
Publication Date: 2021

Variant appearance in text: ERBB2: 3307A>C
PubMed Link: 34604069
Variant Present in the following documents:
  • Main text
  • fonc-11-733478.pdf
View BVdb publication page